Symbol="GRCL"
AssetType="Common Stock"
Name="Gracell Biotechnologies Inc."
Description="Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for cancer treatment in the People's Republic of China. The company is headquartered in Suzhou, China."
CIK="1826492"
Exchange="NASDAQ"
Currency="USD"
Country="China"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="BUILDING 3, 418 GUILIN ROAD, XUHUI DISTRICT, SHANGHAI, CHINA"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="283050000"
EBITDA="-569284992"
PERatio="None"
PEGRatio="None"
BookValue="17.88"
DividendPerShare="0"
DividendYield="0"
EPS="-1.28"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.232"
ReturnOnEquityTTM="-0.417"
RevenueTTM="0"
GrossProfitTTM="366000"
DilutedEPSTTM="-1.28"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="12.86"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="732.21"
PriceToBookRatio="0.792"
EVToRevenue="150.04"
EVToEBITDA="0.0518"
Beta="-1.455"
num_52WeekHigh="6.99"
num_52WeekLow="1.4"
num_50DayMovingAverage="3.102"
num_200DayMovingAverage="2.657"
SharesOutstanding="67715000"
DividendDate="None"
ExDividendDate="None"
symbol="GRCL"
open="4.20"
high="4.85"
low="3.99"
price="4.56"
volume="375619.00"
latest_trading_day="2023-07-07"
previous_close="4.18"
change="0.38"
change_percent="9.0909%"
aroon_positive_momentum_days="38"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="38"
Volume_recent_avg="238437"
Change_recent_avg="0.02"
Delta_recent_avg="0.27"
Variance_recent_avg="0.14"
Change_ratio_recent_avg="0.23"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="38"
Aroon_momentum_negative="62"
image_negative_thumbnail_id_1="112"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0064.jpeg"
image_negative_thumbnail_id_2="1122"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0155.jpeg"
image_neutral_thumbnail_id_1="585"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0014.jpeg"
image_neutral_thumbnail_id_2="569"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0030.jpeg"
image_positive_thumbnail_id_1="976"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0138.jpeg"
image_positive_thumbnail_id_2="639"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0069.jpeg"
image_professor_thumbnail_id_1="1184"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
image_professor_thumbnail_id_2="1169"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0003.jpeg"
